0001437749-21-018621.txt : 20210805 0001437749-21-018621.hdr.sgml : 20210805 20210805080058 ACCESSION NUMBER: 0001437749-21-018621 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210805 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210805 DATE AS OF CHANGE: 20210805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MESA LABORATORIES INC /CO/ CENTRAL INDEX KEY: 0000724004 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL [3823] IRS NUMBER: 840872291 STATE OF INCORPORATION: CO FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-11740 FILM NUMBER: 211146391 BUSINESS ADDRESS: STREET 1: 12100 W 6TH AVE CITY: LAKEWOOD STATE: CO ZIP: 80228 BUSINESS PHONE: 3039878000 MAIL ADDRESS: STREET 1: 12100 W 6TH AVE CITY: LAKEWOOD STATE: CO ZIP: 80228 FORMER COMPANY: FORMER CONFORMED NAME: MESA LABORATORIES INC /CO DATE OF NAME CHANGE: 19951117 FORMER COMPANY: FORMER CONFORMED NAME: MESA MEDICAL INC DATE OF NAME CHANGE: 19921123 8-K 1 mlab20210804_8k.htm FORM 8-K mlab20210804_8k.htm
false 0000724004 0000724004 2021-08-05 2021-08-05
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549   
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
 
Date of Report (Date of earliest event reported): August 5, 2021
 
MESA LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
 
 
Colorado
(State or other jurisdiction of
incorporation)
0-11740
(Commission File Number)
84-0872291
(I.R.S. Employer
Identification No.)
 
12100 West Sixth Avenue,
Lakewood, Colorado
(Address of principal executive offices)
  
80228
(Zip Code)
 
Registrant’s telephone number, including area code: 303-987-8000
 
Not Applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered under Section 12(b) of the Act:
 
Title of each class
 
  
Trading Symbol
 
  
Name of each exchange on which
registered
 
         
Common Stock, no par value
  
MLAB
  
The Nasdaq Stock Market LLC
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 
 
 
 
 
ITEM 2.02
RESULTS OF OPERATIONS AND FINANCIAL CONDITION
 
On August 5, 2021, Mesa Laboratories, Inc. issued a press release relating to its results for the three months ended June 30, 2021. A copy of the press release is furnished herewith as Exhibit 99.1.
 
The information furnished in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.
 
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
 
(d)
Exhibits:
 
 
99.1
 
 
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
DATE: August 5, 2021
      
Mesa Laboratories, Inc.
       
(Registrant)
         
         
     
BY: 
/s/ Gary M. Owens  
       
Gary M. Owens
       
President and Chief Executive Officer
 
 
 EX-99.1 2 ex_271748.htm EXHIBIT 99.1 ex_271748.htm

Exhibit 99.1

 

Mesa Labs Announces First Quarter Results

 

Lakewood, Colorado, August 5, 2021 – Mesa Laboratories, Inc. (NASDAQ:MLAB) today reported results for its first fiscal quarter (“1Q22”).

 

Financial highlights for the quarter ended June 30, 2021 as compared to last year:

 

●

Revenues increased 17%
 

●

Operating income decreased 13%
 

●

Non-GAAP adjusted operating income1 excluding unusual items increased 12%

 

Financial Results (amounts in thousands, except per share data)

 

In comparison to the same quarter in the prior year (“1Q21”), 1Q22 revenues increased 17% to $34,920, operating income decreased 13% to $3,123, and net income was $1,995, an increase of 64% or $0.38 per diluted share of common stock. As detailed in the Unusual Items table below, operating income for the first quarter of the previous year was impacted by unusual items totaling $(364). Excluding the unusual items, operating income would have decreased 3% to $3,123 for 1Q22.

 

On a non-GAAP basis, in comparison to the same quarter in the prior year, both 1Q22 adjusted operating income1 (“AOI”) and adjusted operating income excluding unusual items increased 12% to $9,136 or $1.72 per diluted share of common stock. A reconciliation of non-GAAP measures is provided in the tables below.

 

Division Performance

 

 

●

Sterilization and Disinfection Control (43% of revenues in 1Q22) continued to deliver strong results with 16% organic revenues growth versus 1Q21 led by recovery in our healthcare services and medical device verticals and ongoing strength in biopharmaceuticals. Quarter over quarter gross profit percentage contracted 130 bps versus prior year to 75%, primarily from unfavorable vertical market mix and higher wages offsetting the volume growth.

 

 

●

Biopharmaceutical Development (25% of revenues in 1Q22) delivered solid topline results in the quarter with 49% organic growth quarter over quarter primarily due to COVID related declines in 1Q21. Gross profit percentage contracted 22 percentage points versus 1Q21 to 53% primarily due to unfavorable exchange rates, higher labor-related costs, and the absence of the benefit of a positive purchase accounting adjustment in 1Q21. With the SEK at a current exchange rate of approximately 0.116 USD, we expect gross profit percentage in this segment to range from the low to mid 50’s.

 

 

●

Instruments (22% of revenues in 1Q22) organic revenues declined by 2% versus 1Q21 despite declines due to the impacts of COVID in the same quarter of the prior year. The division continues to lag the broader economic recovery. Additionally, the division was impacted by the previously announced consolidation of our Butler, NJ facility into our Lakewood, CO facility which we expect to complete within 2Q22 with topline recovery in the affected product lines following and spreading into 3Q22. Despite the volume decline and the impact of higher wages, gross profit percentage expanded 60 bps versus 1Q21 due to improving efficiencies.

 

 
 

 

 

●

Continuous Monitoring (10% of revenues in 1Q22) posted steady results with 3% organic growth versus 1Q21. The division continued solid execution in profitability with gross profit percentage increasing 710 basis points versus the same quarter in the prior year from the same factors described in previous periods, namely better discounting controls, product pricing mix improvements, increased revenues and improved efficiencies.

 

Executive Commentary

 

“Operationally we are leveraging The Mesa Way to deepen improvements in our commercial processes, increase manufacturing flexibility, and reduce the complexity of running our business. With this added resilience and focus on long term growth, we continue to keep a strong focus on our long-term goals while navigating rapidly changing economic conditions,” said Gary Owens, Chief Executive Officer of Mesa Labs.

 

“Overall, we are satisfied with the solid start to the year. Adjusted operating income increased 12%, in line with our 17% topline performance and our deepening investment in commercial resources. The sequential step down from 4Q21 was in line with expectations and we remain poised to continue to take advantage of the recovery in our end markets. Total company gross profit percentage contracted by 430 bps versus 1Q21 to 64% but was only down 100 bps versus full fiscal 2021,” added Mr. Owens.

 

“Looking forward, the COVID Delta variant is colliding with increased vaccinations globally and inflation pressures in the U.S. contributing to increased economic uncertainty. We remain optimistic regarding the continued economic recovery and focused on capturing the opportunities presented in our biopharmaceutical and other healthcare driven verticals. We retain a strong cash position and balance sheet flexibility and are positioned to invest in growth opportunities both organic and inorganic,” concluded Mr. Owens.

 

1 The non-GAAP measures of adjusted operating income and adjusted operating income per diluted share are defined to exclude the non-cash impact of amortization of intangible assets acquired in a business combination, stock-based compensation and impairment of goodwill and long-lived assets. A reconciliation between these non-GAAP measures and their GAAP counterparts is set forth in the table below, along with additional information regarding their use.

 

 
 

 

Financial Summary (Unaudited except for the information as of March 31, 2021)

 

Consolidated Condensed Statements of Income

 

(Amounts in thousands, except per share data)

  

Three Months Ended
June 30,

  
   

2021

    

2020

  

Revenues

   $ 34,920     $ 29,941  

Cost of revenues

     12,709       9,601  

Gross profit

     22,211       20,340  

Operating expenses

     19,088       16,770  

Operating income

     3,123       3,570  

Nonoperating expense

     1,705       2,816  

Earnings before income taxes

     1,418       754  

Income tax (benefit)

     (577 )     (463 )

Net income

   $ 1,995     $ 1,217  
                 

Earnings per share (basic)

   $ 0.39     $ 0.27  

Earnings per share (diluted)

     0.38       0.26  
                 

Weighted average common shares outstanding:

                

Basic

     5,152       4,528  

Diluted

     5,301       4,669  

 

 

 Consolidated Condensed Balance Sheets

 

(Amounts in thousands)

  

June 30,

2021

    

March 31,

2021

  

Cash and cash equivalents

   $ 275,710     $ 263,865  

Other current assets

     39,601       39,884  

Total current assets

     315,311       303,749  

Property, plant and equipment, net

     21,951       21,998  

Other assets

     275,228       275,728  

Total assets

   $ 612,490     $ 601,475  
                 

Liabilities

   $ 213,487     $ 195,248  

Stockholders’ equity

     399,003       406,227  

Total liabilities and stockholders’ equity

   $ 612,490     $ 601,475  

 

 
 

 

 

(Amounts in thousands, except per share data)

  

Three Months Ended
June 30,

  
   

2021

    

2020

  

Operating income (GAAP)

   $ 3,123     $ 3,570  

Amortization of intangible assets

     3,816       3,354  

Stock-based compensation expense

     2,197       1,268  

Adjusted operating income (non-GAAP)

   $ 9,136     $ 8,192  
                 

Adjusted operating income per share (basic)

   $ 1.77     $ 1.81  

Adjusted operating income per share (diluted)

   $ 1.72     $ 1.75  
                 

Weighted average common shares outstanding:

                

Basic

     5,152       4,528  

Diluted

     5,301       4,669  

 

 

Detail of Unusual Items (Unaudited)

 

As discussed above, operating income and adjusted operating income were impacted by various unusual items during the three months ended June 30, 2021. The following table provides detail of such items and reconciles the impact on operating income as reported under GAAP and non-GAAP adjusted operating income. (Amounts in thousands.)

 

Impact of unusual items on operating (loss) income

  

Three Months Ended

June 30,

  
   

2021

    

2020

  

Operating income (GAAP)

   $ 3,123     $ 3,570  
                 

Unusual items – before tax

                

Non-cash true up of cost of revenues expense associated with the step up to fair value of GPT inventory due to application of purchase accounting

   $ --     $ (436 )

Non-cash true up of cost of revenues related to adjustment of the value of intangible assets related to purchase accounting

     --       178  

Non-cash true up of administrative expense related to adjustment of the value of intangible assets related to purchase accounting

     --       (522 )

GPT integration costs

     --       416  

Total Impact of unusual items on operating income – before tax

     --       (364 )
                 

Operating income excluding unusual items

   $ 3,123     $ 3,206  

 

 
 

 

Impact of unusual items on adjusted operating income

  

Three Months Ended

June 30,

  
   

2021

    

2020

  

Adjusted operating income (non-GAAP)

   $ 9,136     $ 8,192  
                 

Unusual items – before tax

                

Non-cash true up of cost of revenues expense associated with the step up to fair value of GPT inventory due to application of purchase accounting

   $ --     $ (436 )

GPT integration costs

     --       416  

Total impact of unusual items on adjusted operating income – before tax

     --       (20 )
                 

Adjusted operating income excluding unusual items

   $ 9,136     $ 8,172  

 

 

The non-GAAP measures of adjusted operating income and adjusted operating income per share presented in the reconciliation above are defined to exclude the non-cash impact of amortization of intangible assets acquired in a business combination, stock-based compensation and impairment of goodwill and long-lived assets. We believe that excluding these non-cash expenses provides the ability to better understand the operations of Mesa Labs.

 

We provide non-GAAP adjusted operating income, non-GAAP adjusted operating income per share amounts and non-GAAP adjusted operating income excluding unusual items in order to provide meaningful supplemental information regarding our operational performance. Our management uses non-GAAP measures to evaluate the performance of our business and to compensate employees. This information facilitates management's internal comparisons to our historical operating results as well as to the operating results of our competitors. Since management finds this measure to be useful, we believe that our investors can benefit by evaluating both non-GAAP and GAAP results.

 

Our management recognizes that items such as amortization of intangible assets, stock-based compensation expense and impairment losses on goodwill and long-lived assets can have a material impact on our operating and net income. To gain a complete picture of all effects on our profit and loss from any and all events, management does (and investors should) rely upon the GAAP consolidated statements of income. The non-GAAP numbers focus instead upon our core operating business.

 

Readers are reminded that non-GAAP measures are merely a supplement to, and not a replacement for, or superior to financial measures prepared according to GAAP. They should be evaluated in conjunction with the GAAP financial measures. Our non-GAAP information may be different from the non-GAAP information provided by other companies.

 

 
 

 

Forward Looking Statements

 

This press release contains forward-looking statements regarding our future business expectations. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections. Any statements contained herein that are not statements of historical fact may be forward-looking statements, including statements relating to: the duration and impact of the COVID-19 pandemic and the myriad of its adverse effects on our business ; our ability to successfully grow our business, including as a result of acquisitions; the market acceptance of our products; reduced demand for our products that adversely impacts our future revenues, cash flows, results of operations and financial condition; inability to consummate acquisitions at our historical rate and at appropriate prices, and to effectively integrate acquired businesses; conditions in the global economy and the particular markets we serve; significant developments or uncertainties stemming from the U.S. government, including changes in U.S. trade policies and medical device regulations; the timely development and commercialization, and customer acceptance, of enhanced and new products and services; projections of revenues, growth, operating results, profit margins, expenses, earnings, margins, tax rates, tax provisions, cash flows, liquidity, demand, and competition; the effects of additional actions taken to become more efficient or lower costs; restructuring activities; laws regulating fraud and abuse in the health care industry and the privacy and security of health and personal information; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; and foreign currency exchange rates and fluctuations in those rates; general economic, industry, and capital markets conditions; the timing of any of the foregoing; assumptions underlying any of the foregoing; and any other statements that address events or developments that Mesa Labs intends or believes will or may occur in the future. Without limiting the foregoing, the words “expect,” “seek,” “anticipate,” “intend,” “plan,” “believe,” “could,” “should,” “estimate,” “may,” “target,” “project,” and similar expressions identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. These forward-looking statements are made based on expectations and beliefs concerning future events affecting us and are subject to risks and uncertainties relating to our operations and business environments, all of which are difficult to predict and many of which are beyond our control, that could cause our actual results to differ materially from those matters expressed or implied by these forward-looking statements. These risks and uncertainties also include, but are not limited to, those described in our filings with the Securities and Exchange Commission including our Annual Report on Form 10-K for the year ended March 31, 2021 and our subsequent Quarterly Reports on Form 10-Q. We assume no obligation to update the information in this press release.

 

 
 

 

About Mesa Laboratories, Inc.

 

Mesa Labs is a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, medical device, industrial safety, environmental, and food and beverage industries. Mesa offers products and services through four divisions (Sterilization and Disinfection Control, Biopharmaceutical Development, Instruments, and Continuous Monitoring) to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.

 

For more information about Mesa Labs, please visit its website at www.mesalabs.com

 

CONTACT: Gary Owens.; President and CEO, or John Sakys; CFO, both of Mesa Laboratories, Inc., +1-303-987-8000

 

 
 EX-101.SCH 3 noticker-20210805.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 noticker-20210805_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 noticker-20210805_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 noticker-20210805_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 mlab20210804_8k_htm.xml IDEA: XBRL DOCUMENT 0000724004 2021-08-05 2021-08-05 false 0000724004 8-K 2021-08-05 MESA LABORATORIES, INC. CO 0-11740 84-0872291 12100 West Sixth Avenue Lakewood CO 80228 303 987-8000 false false false false Common Stock MLAB NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document And Entity Information
Aug. 05, 2021
Document Information [Line Items]  
Entity, Registrant Name MESA LABORATORIES, INC.
Document, Type 8-K
Document, Period End Date Aug. 05, 2021
Entity, Incorporation, State or Country Code CO
Entity, File Number 0-11740
Entity, Tax Identification Number 84-0872291
Entity, Address, Address Line One 12100 West Sixth Avenue
Entity, Address, City or Town Lakewood
Entity, Address, State or Province CO
Entity, Address, Postal Zip Code 80228
City Area Code 303
Local Phone Number 987-8000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol MLAB
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0000724004
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.noticker.com/20210805/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports mlab20210804_8k.htm ex_271748.htm noticker-20210805.xsd noticker-20210805_def.xml noticker-20210805_lab.xml noticker-20210805_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mlab20210804_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "noticker-20210805_def.xml" ] }, "inline": { "local": [ "mlab20210804_8k.htm" ] }, "labelLink": { "local": [ "noticker-20210805_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "noticker-20210805_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "noticker-20210805.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "noticker", "nsuri": "http://www.noticker.com/20210805", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mlab20210804_8k.htm", "contextRef": "d20218K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.noticker.com/20210805/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mlab20210804_8k.htm", "contextRef": "d20218K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.noticker.com/20210805/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001437749-21-018621-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-21-018621-xbrl.zip M4$L#!!0 ( !% !5,!9)1KDR( (VF 0 - 97A?,CU= MZW?;-K+_O/TK<-VFZYQ+*7KX;=?G.':2S3:)T]C9?+P'(B$+-44P!&A9^]?? M&0"D2#UL)[8D2D9/6]LD" P&,[]YX'744_WP^*C':'#\RS^.%%YN[=7A[=$K\_"7?\#[_ZG5R#L6L80J%I#.D%SVTBA@R9GH,_)9)(J&I$;V M7FV]:C5:3;)[T-@]V&Z1SQ])K79\U&>*$K]'$\G4'QNIZM;V-NS3B/;9'QM= MD?2IJ@5,,5]Q$6T07T2*15!:L9#%/1&Q/R*QJ M)OE_V0%I-F)U2/2#+NWS<'A ?O^>"G5XR?M,DD]L0+Z(/HW,PT,2TR#@T=4! M:?"(-.I-'AT2/TVD2 X(394XQ#;CK*$^3:YX5.L(I40?OHEO#XEBMZI&0WX5 M'9"$7_6@>5M,B5B7@;XB025J,^+^.4;7/SVBGWA$LH1W;5=&?8.Z.L=O;GN\ MPQ79WZ\WCUYUCH]>82GX$1__\@/4AJP[;V)_CSHR/IQ!7['NL9H/1S7I$=5_ MWM"$TT@=1"@MX6&A*SZ("DL.35<.\ /-IX],4O*!=B0YB2*11CXT\98G4I&_ M4IK %^0+DVFHI&'B;.HF.OX0^DK49(QX4@Z,]_<#O68#(0*/G(I0)#00V#&/ MG*17*71ZVR.HG5"0X//??]UK-9N').,2?*!$PG$XWT=^G6Q^.KDX._GKX..' MD]$(X_M1L[7+I Q)\M]S=Q"9:C''X _W=T /%B"!7_!G,%;?7HFO*A@O=L,2Q6'4K2H"CAR6OM3%YS7: MO^[O[.Z;X<9F'D;>730]@71\83&'LQ)A9: M$&0:WT%CR"-6ZS$T+@?-5C:DFA#TK)I@,J ";([=^F&*LD'2*)4IF"6N6+^$ M/ZT7Y(&RM[IVN5.PR]:OTW[.)NV#[Z>0'V"@12II%("/ UQCL2(P,$1": *: M2A5]N>K>R?O(>AA#F M3;-E6.]O[2UOOP6.S;AHEQ'/%/6:K;9'@.\D8BHK-P!OZ+>FM[^_C:_R%HCH MDIVM%P2H^ZU1;^_I$0IXF*(>F9&"$E!#'SHHE?"OZ^1$0JN*\A"*V/Y]M:KP M7JN"1506BL$4BC/7S3BQ&:.@%<,H=L-!:@ROD&@._/5M'%S6."4@$,:*?]ML M[VR]K),WN6IB5:7"4^@8B#0,2(_>%)E8Y*&F% =FY;WH\XA \)_A9(=*#@SA M/RZ\'IA)U3/".AMM'X>T!FAS-3DY?Y]IB1;IF)",GF%@ Q MZ%C!(FK4>:E3E1P>Z9 ^8"&_09<"/@*]S](D XX@M8-6[8I&W!]5 M)\8$-ML-THEE1G_!JP!F[&Z_\/ 1\!M&BG03T0T6_(1JSFXLV?A"JHPD^3!(N42-.UQ\"/6^B, M8M"91KW9W"%?+\X\,L!^Q #P,Q%.CQTX3Y)=Z>:!"XFN6V,8-@_>$S[MP\!O M-W0J??=0.CQR>/0$(3P8ZQ3%3@+ZM&:@SX0C83%!NP[P45&Q R9CB#Q&L&$5 M&^78!+-H9BW&6-@JA5UY*)Q9]SJYA+^#S/7.7"!I9C6,I>XD@@8X$0)O15^3 M:AP:"%Y $M&[HF$X]'3AO*KQ +L8@H,64SN1AR 3:=S-HQ_TD5ZG*F00%'[Z M-^E2C(T4ND] %+XL3(^=CUX/>MSO%2 !"F,0&C)@&&(V\*.%T:7&[Q'&CWPS M#7%=]!>!*H"2((5:#)^[(@2YSP&?.*@-?( S$#ZF4 M?VQ\?O?ZSS%X(AJ?LGEKG,3&B>O13+:>A->/<.Z^5-?;RR]Y9<69<#M_3 H- MC'W;Z]; 7$\^1" EG]]]^OIQU HE6<.?3]Z]J;W^\N;DS]K) MV\LW7PX(#0=T* \M8!]@',]*Q!P2FYX@+9S$]W%V]X#\VM#_P'?4OP9A2*.@ M5GXUP8!_G4UG@%D*\)/=OSP__<"CZSL9D/-AJOS\\,J";+#MR(]WQ9G#]3&' MI\:V8 ;VHX@X+E$ V-IL-F881O H==I, =8.RP%X>\+Y+D#C#).6>??LEOFI M-C70DL%[4GJ7!_2O-MLF$SGF//]@!1][G;J5Y:FB<"YSAP+558#([$#WK?*+,'6O?)#6DE]LK: NE7X?@QC@P[8%XA61E MSFLT3+904$D#,J]""[ .BX=L:MO.7AO'#'TB3#:%,.P) MO4+I..+'J"1ZQ= W.L0I19/T8C&+2G*3):TP:0W*@'-R\-)G4K*"3 &*1RE* MB9R@(6 M$WZ/CT92!R9;">R/,IL(;-DH_%"09Y I* M@C ;FR'9]Q0*X1L@*2:!&$0&L;?0Y=8139$*$VAH/3-8.L" HD\1Q 67)I%< M%$<%@0N(] TU)L5&8^/Y88:Y8)U(1;IP)M+,ID7#AR1R(=3::D_&"] Z3L9V M4J7[(2),"V'_P"LJ%NZFX C:Y7^XU"V7<*.)'V'(M(2OB^Q^$.):0Y9(!C0) M3!!K N@S%BI*;!TX P<^.4@QEM;#/Q+0&^J#T;6") M]9'#,Q&PC] 3%0Y4@<86L?%#$>.:T!1<,_ -+T830696$[,-AA-4QC(%J8T M@@3@+AK-7EB:L0,C)/:I[-F4H9VK 99I[94]QE31@)BIV83EQ8U:&9U&VJP' M6*9>3R9G/J(9"/M7+M XZ1JFZR743[,4";%P<@H:$[$SP?KN^?/):7 M*:S+ M[6B:"7;C(&#+6CY&Z1+:AZ'-9O;@;] %M,D8#$( "SA)J/\]Y8D15II[$HB; M':N8GIEPKW6T=B&@PH"/Y@JQ,9YH&P$-7 D1#'AH1%Q["CA%$-C6IDS:@V\^ M8$PKMIS&/)L"X@G1S[4#SY(8S*&>VY!],Q#\[SE+(6*YBHF99U664L*J[CNTC[_2S&VOP: MT13$&"V46;N7K=LJBC35B/.1)C[$^TVS[O[.57V/=@CNY)HV)@/&O+?+3ZN[-L:J &#\)7Z::T%9 MZ[?'D4'GQC+%V,?7TQG[H#'1S.;(067V38UR>C/,)#&[K+),V"A;]@A!L)W9 MV7MQ9X+M2<2KO ML!+*CS6,XLILG/[J4=CR'R(,_-NHAHT']K+WQ^-Y,3:," MM() 17]L[&R8]FA?%9N;IDJ/8.B$@7KB;.C]^]S,OY>]A#',D:J>)&]P DAG MICHV#=TYSO8BF815]M^L08+ D(?S&26;%5RL.DT5E8(XMN8NCJVB.+86)HX6 M?'-5;L:W-J^27'4V&Q[!?U\N2VKUCL0?$/ +_ID0,R-I68PL\V_8>_&][^^73HF0E'(UL#^4]/D1K M(F1\\1@)GZWO;+G]8NK) T]+C=GB,TM?@*A(#!(: M ] D*9L_<^X$X_9"1>&)6_L!49AL>2&BT-KW]K>:LT2AO5Q1>#R>;F]K*%U; M/#T54A672ZPUKC[6N5L:XCZ8\F;+VVWL+P>8'T;CLO'[T4(P%YA_"LE]"-NQWKYXF8/[FJSB9I-UMB05-!'@B;6\5G.FBCFG?$&C MORP_O.&UMV:&9,X/KS26;A2.!\)%8)%TGOBJ>^+[7F-OSWGBSA.OG&3N>+N[ M2[(4SA6?M_G@HW4<:VH\*F@5-H[U*4S.]WZ>OG?;VUX6H#K7^]'8^4E$8MS[ M7F?\? [.M[?;V':^M_.]JR:8+6^ON>-<[W4R'V]H@IL"\>#$KDA8MD5%T=OU MSN%4T#X@\&\UEY1T<6[XLMWPW>TMYX2O*(J^SU&3;-ISX.[;)[#2Z/D,G/#- M[=W=BD#Q@VE^Z=SO=7:_-[=V9B;I%FPB9JP'?^D<[P?G;?(; ];:4-PK[6V0 M]D"DN)MR3-RKM&C\X53KFQ\JD;R91>.R??V'\W*Y:]4?+:F5L"9W26JK.=/% M66PVI[V@;,Z,..1N\7_=ND<2[RJ \/MNTH8&MKWT7!' 4W#'>\M#1,E MG!%_V]D])3F=9QM6U.?91*XM\VPD4[CYC\=\V[!J MOX#Q6.X!6\\U(?$:DP_.-UZP?[3M-;=;SCE^GL[QEK?=FAD9K;QWO.[>VIG) M)SC(7#ADMF?_3D2S9GWQNWMUIMWGR%]#[73V'?/,9R&H3/.)']M;^VX MP%L[)I;/WR59Y2//W4GC3^)BK,I)X_<>*>[.<%ZDBN4W-,1K6M8YQ*[^BJC6 M[K:WVW2'7KM%42 +.VUO;V?F(O5J!. N9SD38L_U)9-^FB1X/Y^YA&^MT77] M=QNV[SQ@V)WYX38=+E$R]_:6M#/='?HQ#P,R[>AK>Z_VLS$I%;05H&K-;:_M MSL!^KK-B[4;;V]VJ^+R8<\MGNN6?$SR(3PT]$H<4430*=/XCQEMJ/1(Q=ZG MPB/=IK>_[0#UF0(JCO[^^B[-6F\O-4MSK+\O^@S2&YA];LU>)>GR&RZ_L4S1 MW%W6 MYE)3C6VQ6?G>!X!L;DV1VXM--L>5O[2YK9=$?OGX<]0%*0+G2CU^.>KE)_WSR[DWM]9OOER M0&@XH$.9B1+:Q(B5B#DD/69ZU<)QLQ;_UX;^9YHS8%]-,.!?9],9@%S\Z>Y? MGI]^X-'UG0S(^1 _X&2*G]C\^83G4K@3#C)Z5^2$ X^P6Y_%JG"26]VQAZ^,SCM8Z+;KGX^P MGC1VNOOX G< Q^+%M7P(@#OJPAUU\10BU7!G2JQ:3FGC^!S '_\% M?!41$5V 6$6C*XXA^?HOEZW@S"[JTUYSYGTK#EG7>]-:VVMO+^FX!;>,YFF6 MT=0Z%$^#!4\U9I$TP,IN\?<%W_7\H/##K;!Y9!S;\IK[55D$^30YC*HM97'K M:WYJC)M>:ZV<]^#N5>.BXF$B)1"*J/<.TR+JOG]GWFNTE!0-N M]4RU)+42UF8VU7O@!\V\!:O":V?]) -'@3'TBN&<5%]$QK1)(E(E%8TP=#ZXQ[R]GML2V)*8YYBG;WF"DY:X\7: MS6WG*3_3Q4-;WO:RCC)UZ8A' ^:9R30XR%PX9+:7=?>6@\SE0^;.3L7O7%GT MYO[Y[_B>-])F[#SJ')\Q!2.)"]N_1JE,:4C>*]:7^J;CS:\130.>9W>7R-XY M=/Y$DH!+/Y6X&)5VQ WS)A/=>!0/G9D&'["$$=Z/J8^O.T."38I4DM3RDFM> M!FF"'ZD>@_]PDW%?Z$W&##<9D_P:==S162>74*HKPE ,]#=Z[W^0,^# M?+1DZO=L]4ACPGP1^3R$,MB,H8G@CH6)'DDH'(L$*08/@B4$5T7I2K(E4K-[ M7"=3]Z_7%RD?3W8<0NEXBNDBM'I''>PV*G/4 :#+>RN'W3&-* GF9BBD?&DE M[.Z]I^[8@P4<>T"6?,.].V?!G;-0J4WQ[IP%=\Z".V?!):#<.0L_M.#YP2MD M6E5:IKW$HDA163U*6=*[&L#05N 9!; /3$*8JOI<0$NF3ZN.WF M(;PC'=85"2.*WCX@+[%":X"@;UDSV*TY+@6ZIZ4G71%T3UNKMC#H(8.TD):> M=)G0U+;<:J'[D.J3B&H^E3V"UIRD,>94?2%U;C5A-RQ*@01[B@8>3"1\3C&# M/^"JIZ<$I&(Q?J<$Z5*>D!L:0D7P];O/EQ#/0 U*)$,2P$,H0N,X!.YGAQ[% M:>+W*-;L^YC^!]O_O**>:D4S&\>UFIN0K_9J_X6(P>;6[,WO"Y^7?&[9X;;/[I\RD'UND#UCZZ=6LC(-W?7 M=['I<_2W:=#G$9<*)P%N6.YM.YQV..UP>H5Q>G.[M:2#>9P7_1B,-ID+Q:X2 MDZA #WJMCV.>TVFA2YC5FDGYLE#87<6[7*FLQ%SK[*MX9Q\X[J[A747382[= M?=#R9+O6Q\X*EJ8$U]?25-"$. _]&7OH[9WJ'/H_?P_=K6=Q!V0^S0I5=NN' M*7H090NWSJ;++5EU2U9_ELYESR^O_Y+55J,BD=3C[X\O;RW:[G*N]Z7F;V M>5[":/KD]CPO9<_SIN5S2:N22GN%]:F[[L]O^ M_,39"K?]V6U_=MN?W?;GBB.5V_[LMC^[E6#+#BFJ%2JX[<^KBN9NXX;;N.$V M;KB-&V[CAEOA^E,;-_A/K+%P.SB6;4N\FX=TD?$4D=<]K[J[B)'PE[@QS3!6^V8Q.70@;E+CN67V'&3%=1W\A$L&; NC\Q) M6<;^,5T^RB:%1N$@[0OP)_Z;S]Q,GKI%_>\I3TRCE'12"35+28"V#H_T=Q[P M4?C7M0[%FP'A!<=IA3P3M_9)Q4VAP4L?T6D M!^4CDY1\H!U97W6Y^Y;?>OB :PF]!Y0I"!ZU5Q@^[,[#62X7"I"&27V FZ45 M-"2"DMTT)#*-XY"AG. 741<[J84H85L@*-%/6.JP2)WF1.-!U M&L'K"$!%X:6=EG](!=B27D$D@%_Z%TOMSO2]+B^8D M\&&9/M.\I@6L!2#P++##D.)5MR'U+6J(Q /$QL(@44+C-B )0"6*5UXQN"6 M:BB+/O#9F&JAAU$/TM".,\)-AKS:F8 Q_CN-?"W_^;(33?-D(P;=\TX58;=/ MAUAUP$%($TTVBJ,J2D>QN#4\^O9A "]FH!.,$%NH.+@-SV[#\U-N>)X+O!RE MQV]%,@#GBWP0XAHU^R+'XJ-7Z?&JXZ?VX3"LTH<+,URQ!JBDP!JB*=$]KX6V MYP4K5'9(NZFVE;G7B+;<5R;&J).WLZM!1)9IYV\HC8@)CN&U\3D!%5F"5"B> MN1J^AE"?IGI1G4*G.O, X5,#?KGI!XC7(#CF8")A"6?H&V(K-IPLT8MP#PB) M)!GR3\"L%TBVW 'X!.1D.@P%XK C:#[*AKK03C^'OO^[M;QWJ9X6($CP]']Z"QPP ,L,2613. M;,FG1W3LW W% 'XOQA"CL%@WD5M@&/% $VYI@1B/\R''SP4Q?TTI(GE.H96B+PWS%8E 5IY%XA%;Q78%8K8BG(RII#@ M7/;[.,JYI_&U?E$'%QT&(,)OBI+@]R (8)H\74HEX+*1&)Q;'^M"^OHLT#R" M5H$9B"YI2,=E10'4 5,*E.EOP7D!IPY'RD8>AI7@!2OPDI.";'DXS"SJX>^! M#0(&(QG"!\@.' [;; $(BLN&/2WZJN=-1J->%AL8E(6_LRP-_$83C/1U6&!? M*GJK! ML\B$O3I+T<>8 #[!<<#45 +!S$"[@[*@>%(E*<9"6JE1,CF*@'T=TH',ATO+ M TT-:VD'@=J*9(_1$-Q;'V$27'08FJ0@F F_H?[0\M^'ED"U$#W-1QJH0:]U M5PI^; Y02J>VM*2%E/>176"=0F2FSUA@.([HD0L3+E#,9E4 ;3!X%XFV@L+W=7[% M$*(1NDZ^00@$PPF\[W-E\YTC*CW]YP"\9VV<6JW&H;';GOZK>9@]E8Q=CS\# M2 ,ICZ%+XV\,I>-/(02,QI_9CHP_UG[)! V]:4]!EWA_"@W D?%'"A""373- MXE'^6*L,< M!'9B! V3$#D_9X=WA':Y&G?P+E!WPVK-98\FL^3599L-HC'VG MU*]S&>CO8/+2RL>H;L+-R['&=2PL[W)_3(2.UL$DB&Q:*'?-L+MZ%+I:,\ B M11ITC(6WDDF- <7KG&6U[>;.;73#$Q%9?PV3/<"S08]C"BPQ M43B:665RO&C8C)WJ6]4;%>VPH4#L20WR)"+T)EU=[8 ]U-TU6 -/%>9$[(@A M(Q-TB8!Q.NA7]PQ#-E"S.$5#*:Q]!YO:24?NK]9OB65H")OV$=TR^0[MC M@*J R*-\QX6!_,P5>),AZBG8=:[EK>!+8 TG483<^,)BD>CD'@08?0@8:W]J MOQ#K'#(46)T+^D@38'>[Z1$\HL2 ?8H9'1#X[RE*ZU\I>$:(C[9*6:SS+ST? MH\$4NTA$!P)0XWO#,*1QD&71BQD6C6OC<97+K;C>@76T.!2]=38YPRS(M[%-KW6:H_\*S[C"ZW-Q9?Y4XG1K>2=AG&%06SAE\; M;U<$UN:"GT"O%K+LJ=(F)1$W!OVS MX8$A"WF795U'Z;9>:QBL_%S+6W3>15*V=;2DPAC_FBPBCK;2F:8!Z\"O#/,> MH/*#P: .9- 0EQQ &+H.6GYZ_NGRY/3R@+RC$->>#T"VZH?D,UA_[8@;X7QS MKJ>2_BUZ$;F@UVBN3M_",SV!7%B(,8:"'OG?9JW=:-?V]W9K>V"2YMF164[$ MAY.+R]K([$YU"Y[4W&?6#G[IB& ($M)3_?#X_P%02P,$% @ $4 %4S#( M==-W#P FFH !, !M;&%B,C R,3 X,#1?.&LN:'1M[3UK<^*XLI]WJNY_ MT&7K[,E4Q<80,B$D0Q5#2)8[":2 J=U[OYP2M@@Z,38KB03.K[_=D@TV,0DP M>3"SF:W9Q-:C6_WNEN0Y':J13Z8C/Y"?^">_R MN@G&% J64[ ."LG9^4I$#O(\D(H&+IOWEU[6^J!O(?_GU677';(1C3OSJ;( M@=2 &"$>^#Q@?W[I7.:5H($JL<@6(6Q!4.7T@ >\20L0 M-O>IG L0EV&I6#AZ3.1,CSDSGN9$F@M:)U2FPAP:A5$+:>9/2[.UK -J. D\ M)KQPQ%*C.V<7YQS6>R-M-QPE^+L>=Z>9EN,)7#S&L[D%#5G")JT;2L>9$H$- M&4/<Q"V M9&F#4 ]I!2\SN@:AXNXM2S,[?HD"@6,*3MDYS%5/AXQZU0^_G"JN?%8=^;0? M-9;^5;ZUP4^RO";_[G*N'@6*!LGJ@/3GBFJ?/.<6F M*F]\5+YZFCL3HA^,: C[L\JY+>_)J$Z MZ?$1DZ3%[DDG'-' O#PA8^IYH!H5XO" .':!!R<$."5#42%THL(3H(K'[V)( M'I=CG\*D8&99KOI?'T[YM((8,1$_<,]C0?0 O5K&"ICE3%4'_:N']"A_S9& MHJZ"3E1J(Q9X\%>=^_0F5QU07[+3?&J*C>=L!,"L61TF%=1O F>F7]DL5W7@ MSU&QY#BEAP 1'YY$>#T&4HND_@"#6=%:JT'N$1[N25OSS9*%*6I/TXQT5G 8* M) 5B$_]D1,4-#RK8G*O^]NN4.B<&$, 9BAC,D/&;H:J0@_$4-"KT4:%^=?2? M$]*G[NV- "/M6DVZOU&MW3 M?+_ZYAAU&_5OG6:OV>B26NN,-/ZL_UYK731(O7UUU>QVF^T6V0D\_Z!R",Y$ MA<$^.;/K-BDZAZ5C1,VP-OG_IY#]:<3IO-VY(ILYKK/0G: OU($ SE&VOAH& MI_W5VS-]1V@,ZM%IM'JDT[AN=WIO3Q9 Z1J"J F,)BHD7>9B2DL*!R04I'"X MYWTDX8"H(<.FB>"* S(-B'5I<,-(S5787#@^*+W]4G:!P[N P8FR)4.&T-D M3_;B9T8A+&%2$78',Q"AFYGWL;*6SIMRQ^<C6R&7M2[M3Z[4[X/KW2;-5 MMPVW(L8M,:UO>-D7&*;M-:84[ CBB&(JYK@1*HD<,Q>C?(] UL>5)&!Y0&K% MQW?&+^&@:-]G45S\.0<1L,M\/TJ:Y\_ #C=^WAQA$X'K -Q@9?ELH"HZ^XY> M"!W;1_DXUAY^.558 *B>*@'/^.C%D.^8@#24^M%Z53B.(93M@W_H\=#_=6A[ MDLNP3O,Z;V4RAOS.I9*MJ7 ):XD%;$PN%1N+\ ZE/&TNC48V S"$X\@6=K%W MW53&ZJ&WJ?&L8^)$O?!1LVF:C 8"F?0&1KGB>8E-&/ M2Y# PH;B6B@"/>(-IUUWR_J99W7IQ2D05'2VTQ37TY+B9^&(!2J+' MPIY&2&"V,!8 GX^I3]B4N1/%[S") (O*Y'<&)[$)_"G=843!ZQ 8[O\?'V\1 M99:=8K&\D1L$. 0![::/>Y,<;I&(__9KN5@X.I%$,9^-AV' 2*!#E'W(?%U_ M@JZ64,$H,-AC0-SURC8+QJ,AJ\'X.:L/G(,LOEF;37L9@B9<([Z)B.JX?&25 M'0,=.'$?H*[TG0?>:676P\MU&D MQ_PI6:W#9#UR;!,G]3'1Z72R8H: MP(H()2+"/.%Y22)$>,/JDXB3<6)OJ#,!,2D5#R-A7]H3PJV@O<(1J9]W2/' ML:'CUGX^K>#OXOIRXMH-P>$ X.;*[": -3_ 61U@32X H/U0T$ME*A5*"9D M-;5I.9?4DF.;GN_"NO/">BT8VE4\@Z;/'*#S%NW! (/.G1=:0-YR$]@_:6D+ M)<\J[O4_KB?"IN^[$/]H0MR4 MP01D*H: \U,ZVCY$&0<0\L?)'=YN8\#@:O5#I<)114(HX>%)U/DQTR7K8_K% M2!S:AV]0W^M7>WB4WYSA<8?$AOEG-/24!Z]564T1T[./'RZO?Q:&B77X; M#@FJ*W3=V:@?^N_,V2GU:45'B[3VL-CS@ &]'W)W^':[5_WJPK2_)18QN_L9 M04;D='_9:(\U8O066RA/"N!JH)'JOR[0S)5^#\UV>>\HBDEFA6)?>R39('V6_"93)\07-H!X9+0@$ ^B%/ QG@#&33"/R/A MFX-'- 9W_3/5CS_8>QR"X%O(IV./&,$-=% W-1%;FF M8?DS!'[/ 30J:@!+@Q;![KB$<:"R-'"QP$Y=?54?.^,'!#PJ/&GV-G'^<>8= MHCTZKTXD-=!.W[&+^/[*?'Z5^ZB/WG]]@?NV;WC_51N+[Y\S2X )XLW M6@-(JGJ#KW+5I;G.>YWY9(FX@42!0Y(D2V.' POTZ>%+K$>1ZXO6MZNE5:1_ M)/EU7;MH6%\ZC=I7JW;>:W0JA/KW=":7F9!:;M(@/Q&C?E);WB003,\BPBDG[1Y87\R-M.QR67F/;H5]M M]AI7I&@[Q>S<_*TV "S3J/[[;+7)>USTKYN=&J]9KME[GR?-UNU5KU9NR3U M=NNLB0V/5A9V,)C>(JM)0$F*W(&Y)=<.2/I&XSZY8I*22]K'PV"AX*@VS<"U M(8Z6$W"H%'PK'G$5X-FI1'_O4^U\P<'B-3AHG/CP$]TX^EE9X=0=S 1 9=#& ?!/3/Q ;.0][GBAP?VX6= M"8*?G3V8$_)@_D&O!"T@66DJ-M(Z.$] ZOK[0"J^8(M7:6"HP1U/F$%T%!/. MO$3J$:H4=6/ZXHFS(<3(.F#K,TB.( [4!]'Z^L 9\^:KFK[ZE+G>.9S?-_.B2\/1XI/QY.H,,;FPGT0Z M%V;_V'8*"6.J/_)QU6CUXB]K_-[\TNRM]=6/G=GU>P7/'>R_J_/>^)NP6O MZ8PC2R,K.^EA=U]45E=&'Q>I1X/933YLMLSQ7!7]Q?<(V NB=DJ)^808F_ZK M>%0X*I7Q8W-SMF$!R * @KJJPHQDFA,CB6C#TWXB'1"!^:;/$B-^E_E]F1OV M?VM9+N GVW92E.LA4)A<4PB6FEA. )'%VV-G5%%S-WJ/C?K,PU :PV$(!3$2 M:>JOI!+\3.H\:/FASBJ]PWF'\SK?@FM>M&J];YU&=ZUOONWPNM.G'Y=2$X'? M1!4ZG9%K)V09)7QOXL^(2R=8=M=IIKFZ%:58$H@.#:'Y"$Z?02XVP%0+)]*' M J,.F%Q.,.G2TX%1'88"UK8[Z='.1)@;R,2K?9N@9!=?8,<]1;TS2",K9/G[ M6AN<+EB@>VB7MCQ:<&A_VG)DT3[:_G+V2QQG2!%W15'OF4Y51=*Q%;W?.;64 MPB]N7J^.WM[9\QA[GN',VSO)_AXD>TE-_O*_E75./6]XYLD%%3-R M99/V/0MDQO>'W\W3[GB/%*_>^;-S_,%ZH_X' O3&57W(V0 2L?C[0&W]?2"Q MLT6;Z+#&9:W;LQ:'3S(/QSSKH9<8"?@E6C[^6Q[5_P=02P,$% @ $4 % M4]&#D/J# P L@X !4 !N;W1I8VMEE+2T01N?D#3E) M3S+T]R1[.WF3HL\W&#OTH\DGAJUX21%0D&;R.->%F"8K:ZL)(0\/#R.W,E)Z M"1NDIT1(1X+Q).B;O*?]N>_$-BR.F2I_"Z7EZEB!JK1;SVO)_ ME2ZO^(+6!<2XEM]K6HB%X#EPH;84KWD]A,MN:DHXP.,AOLBR@KN M%9)1Z+[;TERR:\6H]7=\+\3-<,!AMX2S$XC2"$PGY& .8Z)5 4G)EZY #.-1 M:-U#.19CQR)[^QH6\>LZA,@F\E,#/)S+\T4@1L/L1?D17N./"\?K0G%4''8J MS\"\# !G]NPU@=\N88/B'D!N@-?HU]B/U<-!'#:!87(DE^U".RP'6Y ;'!N+ M6-$>%HQ-9#<[DL[.IA/#GH'(B2@?8:WWOI>!>>*U7X ?3Z&K[!/V*6J+OW^"7*XKU]F+WN/+-$WA+^.JM;$Y?"]S],&;0[.UN0NR9:LS7QN>_REE_^^QV$*1W6'YEJX"0>(EIFT]$Y\9JRJ#UM+J&]'/' M'<[K/@0)8M2$:+9YU*YJ3I,7=$0!Y<$E:;.]J<&>L+63?M2JKJ:)_Z&;"$@# MZ'E],C8KP O^+F>P[ER#=/6K<&&$RN^\7E[KQ@SI'&TJ,TQ_ E!+ P04 M" 10 53LD)18^$$ "2+0 &0 &YO=&EC:V5R+3(P,C$P.# U7V1E9BYX M;6S-6EUOXC@4?5]I_T,V\QQ":#O3HF%&B#(C-.T4%4:[VI>522Y@U;&1XQ3X M]VN'C](A=@QMHKR4$)]BXE+E?O_SYQ^>_/.\[4.!(0.1,ULYXGM((^"V+P1DR M+A!Q/.?:O_1;S5;@?&H'']N736=X[WGJ:8+I4UO]F: $',F")MG7CCL78M'V M_>5RV5A-.&DP/I,AFA?^#NUNX:HU$OL'#L%7_J9Q#ST*O;S(L,'-S8V?M>ZA M"TDNWG'0B2R/!9*<+0(]JYP\'3XKU0LZ"!,<+ J[_5DH1BQ&F7@SQ!/B9Y')CO#--' -5B\3;='8N M4TV8]R4[E]%XF$[ V_=W)E]#I-+R"U.4$O'V!+^.HZ&[X_H[4=4390*'3\ ; M(8NS3:QY+7O,Z,K%+T#V).0XAFEV(3=(3WYBL9:;PY3Q.-L+7LO81?1VT3+. M)P?3:)&*,<4*>">_;K&*;FFJ-D1@)4#N_ ?;$V'AT? EN^%/(&S,V+,? 5;] M-]6%2DC3:P;;C>Z#O/5?/^OV]M4Z(6@"I./JFC=\B-J'&3_(3-5\\B=?2;QN MMV,U>!F?,9H0R.%8!*V:IYRG,)!3+K'C>@0OE>\=S!#9C&IWA?,H:A"59'$L M.S%D[;"Y$CY#X)A%?1K=RCW$0"P75\&Z?8093@1'5/Q$<1Y!$ZP"?@-9=?,% MX]E$'ZF-N,=2*OBZQR(]7:NG*F#_#1/XF1Z67T=4CR$5\!JCU2!2Y]<4;VKS M I(%^ H8=Z.(0Y)L/]2.%VC9&K#5,>W)RP<^9DO]H:A%5LNB=KJ*G2 +69C[5%-]A6:6A;;K>FO3&6 6RF[JK]5"I>DS^"PV:BK7RFB=^AL]-2O%C&[>S::ZE>'6)B"-L+J5XD4V8DVJNI7 M>=@:D#;JZE>$G&96VFBL7R%B-CIM--6O #'XI#:"ZE=W%/NK-B_3=:TW+ Q9 M&WGU*S@,?JZ-H/I5'!8V\('?Z/^F389]^K*_K_ZH__>5=_X'4$L#!!0 ( M !% !5-M<6WD_@4 -X\ 9 ;F]T:6-K97(M,C R,3 X,#5?;&%B+GAM M;,V;;T_K-A3&WT_:=_!ZWVP2(13N[@8"KA!PKZI;H*)%FW8U36GBMM82G\IQ M:?OM9^=/:5H[34KM[ V$YN0\)\_YQ7:2ME[YST[_M=%HHYAX-O! HOFI1:'V^_O&'RY\ QL+%*Q$%K91R#$#_C$9*_7YX[6L5S5T:X%(]EE[K>$(>B MXB3%A.&1^KB0L<)ALHIS647[DZSB@RH;7TX%&C&)IB%NN>^LLX<9@>">'KA@ M=5H#E?>YQ[B)VK<3'[3Z 8B+]K!U;Z<\;,5BY,('KG@KY4$K?L0')F,SX:&J MW:-,OEUBI=I"&=,56UF83%5T &SS M/,M3..&Z7Y6,V#:8X1AFS$\G2J$DYW),G9=^ZSK50M]3M;\OW;=BBF7>L-P[ MC_D[ZL@B7!_$C#CEQ7,8,8A*K()='J2G)"02(P_:VJZX@L)4^69!8D5W-1$U M&[R1Q72/$SF4=UHJVNVSSC2HX(;!;M^!/XLPY1TZ A8E*S4QYN .QY&J]57" M:W)0EM(T%+DV6A-'WZ4\2O3M(E+)7*CKFEUX!MXPQ-7 *82^'YHD73/ )-*- MLU+T4\^)PB@+C R$1 D7Z[OW9$&FL-7_(R35&NEXP2G898&%SJ[N(._$RKND MQY8]>I *B+&RO MNX1B*CMW"T?H315)V0;N&C060E5OC*/0H3ZP*;!DWNESP>(MS"AGRUL(]&14 M.FHO4$HSV^*F4,012LI P%!6"I*U- !3-==A3SN-H_:%A/AQ%@TQTW*U';(7 M1&]I;!$C%5$JV0 8"MN@BA_&6S[P%IU 3'9D1-)W##OZOR-^+Q@T.6V1(>11 M4;\Y3G;9"[5],T[031 (D^/LE[R!;FOI*8G=BQQ%/EO49)JK#90\\7BB34P[ M9;9"+;]LT7(K-I_8 .;Z)]_:R/>0\I;-.B=26BY1I'ASC"CL5!&B\\D6'\E" MZ(GU&+R2]&5X:5LUX>\A92.E=5Q62]J\@N:8T;FK J?4-EOT]"#F7O@7F9;> M(I4%OX><0D+KW*3J2,@W=1-4ZJN*F1+##!(CA[@;ACT-(ZK=-:E83V&:@V1V MD6+VNZYT"G998/+MJVA0V)L U=_,ZD+JOG_=2&/\!:S40XE@$_@BAT& M._X'(YQC>@M1-*/9S9#JU6MI7,W>*W.9!B 31455JQ"4>PB5S3&(0Q]"XA-. MZ/A!K$88\4(%"_J@FB!L)S)-P9LBRB6M(E!B'53SQ&#S>PQ+[+ X@^1UGOSJ M%GL:C93SP.[@FC#H$YJ&0B@[_IHT2K51(FX5CPJF0CVW[.'2B>,99K6@T1[R M/G2VTEH'**W@?\.1WF?@+RN7MSCXZZZ"*)P;;/F">_/>6_C(:@FK%H=Q?L^&%',:[G8JA M5,UJD]5>P4X3+%S5]PM_(ES"FF]FE(7M>76OIS*^MLPT42YJ_XL9I0Y"56N, M/VR\CS ;"PR_,ICSB9AYIAY=:I\VED;O];A1F='6\\9<'*7J*)-OX'%CN;%0 MTS&#U-R(14D@%R9?0F^LX$2YOR89A1RF65B)(:EFM?5JKV"G"<8'A5LAR[RP M(Q:=BV]8/QQHXO8:"#9RV1H",EF4Z"(AW,#%K[,1*ONS1<3:273%UO7;1R3] MWUGQR7]02P,$% @ $D %4UF&5PY\! )"X !D !N;W1I8VME&ULW5I=;^(X%'U?:?]#)O,<0MK.3(N&&2':&:&A4U08 MS6I?5B:Y@%7'1HXI\._W.GPL%7'B2IM(]0N!^-@^/KZ.;X[Y_'63,N\99$8% M[_I1J^U[P&.14#[O^K_&06_<'PQ\+U.$)X0)#EV?"__KES__^/PN"+X#!TD4 M)-YTZTT6*YZ O!4I>",A%6%>X%V'5^%%^R+R/G6BCYVKMC>Z#P)=FU'^U-$? M4Y*!ARQXEO_L^@NEEITP7*_7KT/X>KDL3=:QP"OX0[@J/ MT+.FUYHG M28L(EL$:X#? ;5DNA'VQXDIN^R(QT[6JU0#[;Y3!SU4Z!6FD>@YI M@->$; :)WB=F=+=Y5Y"LP#? N)N#G(BU>3,T M(IMCF:^-!SF2XIGN\KI2J@9X]C==EB[_,G"M7/54]B00 [NBXGIS M(&R6C1;X F-V+-%WQ_2.E**THQ=7*<"P8C:G"%\)[#'E) M"2N@9P;5RFTD02N";ZQY]C_1V;Q\F,T*Y[<:W"3709:M0+Z*L;%*O?,/\0J# M;QM=3"=4%>;G)DBMO":2:)=BO$VGHB@D"\L;4>IN$R\(GX,ACRR#-;!_W*4@ MYRC,=RG6:H'QM21\:]Q 2M&ULNUAR"@'Y][%(2-L!5N/D! M9N4,.!/#4Q>D)V-/2%SE7;_M>UB":UU",MQU8;2.CJ2K52ZXG1B. MI*>V=KN=*(YDJJ]S].VD<21;+3]$L)/"D2RUY.C"3@='DM/JDQ([.9S*2BU. M9.P<,T?2TI)S(#L=',E++4Z=3DX&UL4$L! A0#% @ $4 % M4VUQ;>3^!0 WCP !D ( !-#L &YO=&EC:V5R+3(P,C$P M.# U7VQA8BYX;6Q02P$"% ,4 " 20 536897#GP$ D+@ &0 M @ %I00 ;F]T:6-K97(M,C R,3 X,#5?<')E+GAM;%!+!08 ..!@ & )0! <1@ ! end